Reply to M.C. Garassino et al

Comment

Suresh S Ramalingam et al. J Clin Oncol. 2013.

. 2013 Mar 20;31(9):1255.

doi: 10.1200/JCO.2012.47.7190.

No abstract available

Comment on

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, Seog Heo D, Rosell R, Talbot DC, Frank R, Letrent SP, Ruiz-Garcia A, Taylor I, Liang JQ, Campbell AK, O'Connell J, Boyer M. Ramalingam SS, et al. J Clin Oncol. 2012 Sep 20;30(27):3337-44. doi: 10.1200/JCO.2011.40.9433. Epub 2012 Jul 2. J Clin Oncol. 2012. PMID: 22753918 Free PMC article. Clinical Trial.
To target or not to target, that is the question.
Garassino MC, Platania M, Broggini M, Torri V, De Braud F. Garassino MC, et al. J Clin Oncol. 2013 Mar 20;31(9):1254. doi: 10.1200/JCO.2012.45.9818. Epub 2013 Jan 28. J Clin Oncol. 2013. PMID: 23358979 No abstract available.